🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Financials Sector SEC Filings — March 31, 2026

Across 50 filings from diverse sectors mislabeled under 'USA S&P 500 Financials' (primarily biotechs, SPACs, tech, and limited true financials like insurers/REITs), mixed sentiment dominates (24/50 mixed), with 12 reporting revenue declines averaging -25% YoY (e.g., Beyond Meat -15.6%, Investview -31%, Co-Diagnostics -84%), offset by cost reductions in 15 firms (avg op ex down 30-50%, e.g., BioAtla R&D -31% YoY). Margin compression prevalent in 8/15 with metrics (avg gross margin -500bps, e.g., Beyond Meat -1000bps FY), but net losses improved in 10 cases via one-offs/gains (e.g., AIRO EBITDA positive turn). M&A surges as lifeline: Centessa/Lilly $6.3B (40% premium, Q3 2026 close), Coursera/Udemy merger (April 9 meetings), Sun Country/Allegiant. True financials stable: Lincoln National $2B credit to 2031, Ashford Hospitality $580M refinance/debt elimination, Old Republic proxy routine. Forward catalysts cluster Q2-Q3 2026 (mergers, approvals, AGMs May), signaling alpha in M&A arb/distressed biotechs amid liquidity crunches (18 firms cash <1yr runway). Portfolio implication: overweight M&A targets, avoid persistent loss-makers without catalysts.

35 high priority 15 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 31, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (despite diverse inclusions like CMBS trusts and non-staples), dominant themes are routine CMBS 10-K compliance reports (28/50 filings) affirming servicer adherence with widespread master servicer transitions from Wells Fargo to Trimont LLC effective March 1, 2025, signaling operational stability but no financial upside. Operating companies show mixed period trends: revenue flat/declining in 7/10 with financials (e.g., KORE flat YoY, Movano -57% YoY, Hughes -8% YoY), but loss narrowing in KORE (-57% YoY net loss), BrainStorm (-11% YoY), and Movano (-23% YoY); margin compression in South Dakota Soybean (-40 bps) and Proficient Auto (EBITDA margin -590 bps). Capital allocation highlights Marsh & McLennan $2B record buybacks +10% dividends and SmartStop $1.60 annualized dividend target. Forward catalysts include KORE $726M merger (Q2/Q3 2026), BrainStorm Phase 3b enrollment (~200 pts), and Constellation earnings outlook call. Portfolio-level: 80% neutral sentiment in trusts, mixed in ops cos; no insider trades noted, low M&A in staples core but supply chain stress evident.

43 high priority 7 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 31, 2026

Across 50 filings in the USA S&P 500 Industrials stream (broadly encompassing industrials-adjacent sectors like defense, energy services, and construction-related CMBS), a dominant theme is routine compliance in 20+ CMBS 10-Ks with widespread master servicer transitions from Wells Fargo to Trimont LLC effective March 1, 2025, signaling operational stability in commercial real estate financing. Period-over-period trends show mixed financials: revenue growth in 8/15 operating companies averaging +20% YoY (e.g., Dawson Geophysical +16%, Range Resources +11%), but persistent net losses or NAV declines in 7 cases (avg -20% equity/NAV drop); Adjusted EBITDA surges in turnarounds like TruBridge (+51% Patient Care) and Dawson (+139%). Positive M&A and capital allocation stand out, with Red Cat's drone acquisitions ($25M+ earnout), Oramed's asset sale with revenue sharing, Range Resources' $231M buybacks/$86M dividends, and First Northern's 6% share repurchase program (~$15.6M). Biotech/industrials crossovers like Tonix (Lyme Ph1 success) and Telomir (TNBC IND) add forward catalysts, while risks include Lipella bankruptcy and going concern doubts in EMAT. Portfolio-level, 65% neutral/positive sentiment, with cap alloc favoring returns over reinvestment; implications favor selective longs in defense/energy services amid stable RE backdrop.

39 high priority 11 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 31, 2026

Across 12 filings in the USA S&P 500 Energy intelligence stream, a dominant theme is revenue contraction averaging -25% YoY in 7/10 reporting 10-Ks (e.g., Hughes -8%, Nocopi -29%, Zapata -100%), offset by aggressive opex reductions narrowing net losses in 6/9 loss-making firms (e.g., Nocopi -94% loss improvement, Magellan -44%). Halliburton stands out with resilient $2.9B operating cash flow and $1.6B shareholder returns (85% of FCF) despite -3% revenue, signaling sector strength in services amid North America weakness (-6%). Impairments and one-offs drove volatility (Hughes $1.4B charges), while small caps like Lion Copper flipped to $4.4M net income via deconsolidation gains. Capital allocation leans defensive with buybacks/dividends in Halliburton, contrasted by equity raises and debt issuance (Exxon $169M notes). Portfolio-level trends show margin resilience via cost cuts but cash burn persists in explorers (Lion -70% cash drop), raising liquidity risks. Upcoming catalysts include Halliburton AGM (May 20, 2026) and Howard Hughes acquisition close (Q2 2026), with mixed sentiment (7/12 mixed/negative) implying cautious positioning amid energy transition pressures.

8 high priority 4 medium 12 total filings
· daily

US Material Events SEC 8-K Filings — March 31, 2026

Across 50 8-K filings from March 2026, dominant themes include a surge in M&A transactions (10+ deals like Repay-KUBRA, SCYNEXIS-SCY-770, Red Cat-Quaze), debt refinancings/extensions (Alerus, Prologis, Ares, Lincoln National), and widespread executive changes/appointments (20+ instances, notably Jay Jacobs replacing Shannon Ghia across 8 BlackRock iShares ETF sponsors). Period-over-period trends show revenue growth in standout performers like nCino (+10% FY2026 YoY to $594.8M, first GAAP profit) and T1 Energy (record Q4 production 1.13GW YoY, FY 2.79GW in-line), but persistent losses (T1 Q4 net loss $190M improved from $367M). Forward-looking catalysts cluster in Q2 2026 (merger closings, M&A approvals), with positive guidance in payments/energy/biotech offsetting bankruptcy (Lipella) and wind-downs (Allbirds). Portfolio-level patterns reveal financials/real estate leaning toward neutral refinancing for stability, while biotech/tech exhibit bullish expansion via tuck-ins and equity raises. Capital allocation favors M&A reinvestment over dividends/buybacks, signaling growth conviction amid mixed sentiment (25% positive, 10% negative). Actionable implications: overweight fintech/biotech M&A plays, monitor ETF sponsor stability, avoid distressed pharma.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 31, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (primarily small-cap and micro-cap names with DJ30 exposure themes), overarching patterns reveal mixed financial performance with 12/20 10-Ks showing revenue declines averaging -15% YoY (e.g., Investview -31%, Nuvve -9.3%), offset by loss improvements in 8/20 cases via cost cuts (e.g., Innovative Payment G&A -46%). Capital raises via PIPEs, preferred stock, and SPAC mergers dominate (e.g., Predictive $343.5M PIPE, Trailblazer SPAC close), alongside M&A activity in defense/tech (Red Cat acquisitions) and airlines (Sun Country merger). Forward-looking catalysts include Keenova's 2026 sales guidance $1.94-2B (+YoY growth) and trial readouts Q2-Q4 2026, while risks cluster around going concerns (VivoSim, Welsbach), dilutions, and impairments. Portfolio-level trends show margin pressures in 7/15 ops-focused firms (avg gross margin -100bps), but improving free cash flow in telco/IoT (KORE +$12.4M YoY). Bullish signals from buybacks (First Northern 6% shares) and distributions (AGL $0.60/share); bearish from Nasdaq delist risks (American Rebel). Implications: Selective opportunities in M&A catalysts and turnarounds amid broad volatility.

33 high priority 17 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — March 31, 2026

Across 50 SEC filings from March 31, 2026, dominant themes include mixed financial results with revenue growth in energy (e.g., Dawson Geophysical Q4 fee revenue +67% YoY) offset by widening losses in biotech (OS Therapies net loss +224% YoY) and crypto (Solana FY net loss -$40.9M widened from -$11.7M), alongside aggressive financing via credit facilities (Prologis, Ares), ATM offerings (Satellogic $50M), and debt issuances (Ellington $50M notes). Capital allocation leans bullish with buybacks (First Northern 6% shares ~$15.6M, Solana $3.4M, News Corp $1B program) and dividends (AGL $0.60/share, SmartStop $0.1315/month), signaling management confidence amid stable mortgage trust servicer transitions. Biotech and energy show forward catalysts like Aktis Oncology Phase 1b trials mid-2026 and AleAnna's Gradizza Concession growth, while SPACs (Berto, Invest Green) hold strong trust assets but face combination deadlines. Portfolio-level trends reveal 8/15 energy/oil firms with production/revenue volatility (avg +20% gas but -10% oil YoY), margin stability in services (Dawson flat 21%), and cash burn in high-growth areas (DiaMedica $29.1M operating cash use). M&A activity (Red Cat $25M Quaze + $5M earnout, Range Impact coal mines) highlights defense/mining expansion, with relative outperformance in Adjusted EBITDA (KORE +19% FY, Dawson +139%). Overall, actionable intelligence favors monitoring capital returns and catalysts over deteriorating biotechs.

33 high priority 17 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 31, 2026

Across 50 filings from the USA S&P 500 Consumer Discretionary intelligence stream (primarily hotels, retail, though broadened to related filings), mixed sentiment dominates (20/50 filings), with 2025 FY results revealing average revenue growth of ~7% YoY in key operators like Ross Stores (+8%), Check Point (+6.3%), TruBridge (+1%), and Proficient Auto (+78.7%), but widespread margin compression averaging -100bps (e.g., Ross -30bps to 11.9%, Check Point op margin -5.1%) due to rising expenses (R&D +15.7% at Check Point, SG&A +200bps at Ross). Liquidity concerns persist in smaller caps (ENDRA cash $762k, FinTrade net loss +332%), offset by capital allocation strength including buybacks (First Northern 6% shares ~$15.6M, Marsh & McLennan $2B), dividends (SmartStop $1.60 annualized, AGL $0.60/share), and refinancings (Ashford $580M debt elimination). Strategic alternatives (ENDRA, Ashford) and mergers (First Foundation/FirstSun closing Apr 1, 2026) signal potential M&A catalysts, while ETF leadership changes at iShares/21Shares indicate crypto/alt asset stabilization. Hospitality/retail outliers like Ashford (+40bps margins, +2.4% EBITDA) and Ross (+5% comp sales) outperform peers amid sector headwinds, positioning for Q2 2026 catalysts like AGMs and revenue thresholds.

40 high priority 10 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 31, 2026

Dominating the 50 filings are over 30 Citigroup Commercial Mortgage Trust 10-Ks revealing a uniform pattern of master servicer transitions from Wells Fargo Bank to Trimont LLC effective March 1, 2025, across dozens of PSAs, with consistent compliance affirmations signaling CMBS sector stability and no material delinquencies or issues. Healthcare-focused filings (ENDRA Life Sciences, Emmaus Life Sciences, Firefly Neuroscience) exhibit volatile trends: Firefly revenue exploded 957% YoY to $1.14M but losses widened to $19.9M with going concern doubts; ENDRA narrowed FY2025 net loss 39% YoY to $7M via 46% op ex cuts yet cash critically low at $762k prompting strategic review; Emmaus revenues fell 25% YoY with net loss up 16%. Broader portfolio shows revenue divergence with standouts like Kennedy Lewis (+71% YoY income), Proficient Auto (+79% revenue), B. Riley (+$299M FY profit swing) offsetting declines (Investview -31%, Specificity assets -0.25%); capital allocation favors buybacks (News Corp $1B ongoing, Cimpress $200M new). Implications: CMBS servicing consolidation reduces risk premiums; small-cap healthcare biotechs offer high-beta turnaround plays amid liquidity squeezes; monitor strategic catalysts for alpha.

42 high priority 8 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 31, 2026

Across 50 DEF 14A proxy statements filed around March 31, 2026, companies predominantly highlight strong 2025 performance with disclosed revenue growth averaging +11% YoY (e.g., Range Resources +11%, Wabtec +7.5%, nVent +30%, SPX +14.2%), margin expansions (Ashford +40 bps Hotel EBITDA), and robust capital returns exceeding $10B in aggregate dividends and buybacks (e.g., Marsh & McLennan $3.7B, Akamai $800M repurchases, Range $317M total). Positive sentiment prevails in 14 filings (28%), mixed in 8 (16%), with neutral in the rest; high-materiality (8-9/10) names show portfolio-level trends of deleveraging (e.g., Range net debt -186M, Essential 3.8x leverage), asset sales/strategic shifts (SITE $847.8M sales), and M&A (Transocean/Valaris). Executive compensation is largely performance-tied with above-target payouts (Merit 124.53% of target vs 118.90% 2024), though TSR lags in some (Marsh -11.3% vs S&P). Upcoming May 2026 annual meetings cluster as catalysts for say-on-pay votes (all recommend FOR), board elections, and auditor ratifications, implying low controversy but watch for shareholder proposals. Market implications favor industrials/REITs/utilities with growth+returns; energy/transport outliers signal caution amid headwinds.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 31, 2026

The March 31, 2026, IPO Pipeline stream reveals three S-1/S-4 filings dominated by pre-IPO preparations and merger activity, with neutral sentiment across all (Bitcoin Depot, VYNE Therapeutics, Churchill Capital Corp X). Overarching themes include aggressive share restructuring via reverse splits in 2/3 filings (Bitcoin Depot's 1-for-7 on Feb 23, 2026, reducing Class A shares 85.7% from 35.5M to 5.1M and Class M 85.7% from 37.8M to 5.4M; VYNE's potential post-merger split), signaling efforts to boost per-share metrics for listing compliance amid no disclosed financial trends. Churchill stands out as post-IPO SPAC (41.4M units sold May 15, 2025, full over-allotment exercised, no Founder Share forfeitures), targeting quantum tech via Infleqtion with Sponsor holding 10.35M cheap Founder Shares (initial $0.003/share). No period-over-period financials provided, but capital events like splits and low-cost equity issuance highlight capital allocation focus on dilution control. Market implications point to crypto/biotech/quantum sectors prepping for public markets, with reverse splits as potential distress flags but merger/SPAC paths offering de-SPAC catalysts. Portfolio-level pattern: 100% of filings involve restructuring (splits, conversions, capitalizations), prioritizing Nasdaq compliance over growth narratives.

3 high priority 3 total filings
· daily

Global High-Priority Regulatory Events — March 31, 2026

Across 50 filings in the Global High Priority Market Events stream, dominant themes include distress signals in Indian firms (closures, defaults, insolvencies in EID Parry, MT Educare, AGS Transact), mixed US small-cap financials with revenue declines offset by cost controls (e.g., Investview -31% YoY revenue but -12% expenses), and positive M&A/catalyst momentum in biotech/energy (SCYNEXIS acquisition, T1 Energy record production). Period-over-period trends show 8/20 10-K filers with revenue declines averaging -25% YoY (e.g., CKX Lands -45%, HireQuest -11%), but 6/20 improved net losses via impairments/cost cuts; energy outliers like Range Resources +11% sales YoY contrast broader weakness. Capital allocation leans shareholder-friendly in survivors (Marsh $2B buybacks, Range $231M repurchases/$86M dividends), while SPACs/M&A amendments signal delayed but resilient dealmaking (Soulpower $8.5B valuation). RBI amendments tighten acquisition/bridge finance norms, potentially curbing M&A; mortgage trusts highlight routine servicer transitions (Wells Fargo to Trimont March 2025). Portfolio implications: overweight US energy/biotech catalysts, underweight Indian distress names, monitor SPAC closings for Q2/Q3 2026 alpha.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — March 31, 2026

Across 50 10-K filings for FY2025 (ended Dec 31, 2025), mixed sentiment dominates with 14/50 explicitly mixed, reflecting turnarounds in select operating companies (e.g., TruBridge net income from -$21M to +$4M, HireQuest +72% net income) amid widespread losses in biotechs/pharma (avg loss expansion +100% YoY in Athira, Sharps, OS Therapies). Revenue trends show resilience in retail (Ross Stores +8% YoY to $22.8B, FitLife +26%) but declines in resources (CKX Lands -45%, SD Soy -9%) and flatlines in tech/services (KORE 0%, TruBridge +1%); operational cash flow improved in 6/15 detailed cos (e.g., Ross +28% to $3B). CMBS trusts (16/50) uniformly neutral with recurring master servicer transitions to Trimont LLC effective Mar 1, 2025, signaling standardization but no delinquencies flagged. SPACs/funds (10/50) hold robust trust assets (e.g., Berto $309M, Invest Green $173M) with low materiality risks pre-combination. Biotech cash burn persists (OS Therapies cash -95% to $270k) offset by financings (Athira PIPE $82M net); capital allocation favors equity raises over dividends/buybacks. Portfolio implication: Favor retail turnaround plays, monitor CMBS servicer shifts for liquidity hints, avoid high-burn biotechs without catalysts.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — March 31, 2026

Across four US exchange filings in the trading suspensions stream, a split emerges with two companies (Classover Holdings and USBC, Inc.) regaining compliance and two facing severe challenges (Iterum Therapeutics delisting and Snail, Inc. deficiency notice), highlighting volatility in micro-cap listing standards amid economic pressures. Key period-over-period trends show inconsistent profitability, exemplified by Snail's net income in 2024 contrasting losses in 2023 (-ve) and 2025 (-ve), signaling erratic financial health without YoY revenue or margin data available. Critical developments include Iterum's imminent Nasdaq delisting and suspension on April 1, 2026, due to bid price failure and Irish winding-up petition, posing total illiquidity risk, while compliance regains boost short-term stability for KIDZ and USBC. Portfolio-level patterns reveal 2/4 emerging growth companies navigating Nasdaq/NYSE American rules, with positive resolutions outpacing negatives but high materiality (avg 8.5/10) underscoring time-sensitive risks. Market implications favor short positions on delisting candidates and monitoring turnaround catalysts, as no insider activity or capital allocation shifts were noted across filings.

4 high priority 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 31, 2026

Across 50 filings in the USA Corporate Distress & Bankruptcy stream (42 new), outright distress is limited to 2 Chapter 11/7 bankruptcies (Lipella Pharmaceuticals, IO Biotech), 1 Nasdaq delisting with Irish winding-up (Iterum Therapeutics), 1 Nasdaq deficiency notice (Snail Inc.), and 1 asset sale leading to dissolution (Allbirds), concentrated in small-cap biotechs signaling sector fragility amid cash burn. However, 25+ filings detail proactive refinancings, new credit facilities (e.g., Prologis $B-scale global credit, Ares 3-yr term loan, Lincoln National $2B revolver), and equity raises (e.g., Satellogic $50M ATM, SCYNEXIS $40M placement), indicating liquidity bolstering to avert distress rather than collapse. Period-over-period trends show mixed revenue performance: nCino +6% Q4/+10% FY revenues to $594.8M with GAAP profitability turn ($5.2M FY NI vs -$37.9M prior); Purple +9.1% Q4 rev but -3.9% FY to $468.7M, EBITDA to +$1.9M from -$20.8M. Forward-looking catalysts include Q2 2026 M&A closes (Repay-KUBRA $372M, Allbirds $39M sale), nCino FY2027 rev guidance $639-643M (+8% at midpoint), and biotech approvals (SCYNEXIS Phase 2 data). Portfolio-level patterns reveal financing optimism (positive sentiment 20/50) vs biotech risks (negative/mixed 8/50), with capital allocation favoring debt/equity over buybacks/dividends, creating opportunities in stabilized microcaps but high short-term volatility risks.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — March 31, 2026

Across 40 filings in the USA Executive & Director Changes stream (March 31, 2026), a dominant theme is leadership consolidation and transitions, with BlackRock appointing Jay Jacobs as President/CEO across 7 iShares ETF sponsors (Bitcoin, Silver, Gold Micro/IAU, Ethereum, Staked Ethereum, Commodity-Indexed Trusts), replacing Shannon Ghia without disputes, signaling centralized expertise amid crypto/commodity volatility. Positive appointments dominate (e.g., experienced execs at Immunic, Skillsoft, AlTi Global, Crown Holdings, Amrize), with 12/40 filings showing bullish sentiment tied to growth strategies, while neutral sentiment prevails in 25/40 and one negative (Rallybio CMO exit). Limited period-over-period data highlights T1 Energy's record Q4 2025 production (1.13 GW, +YoY sales $358.5M) and improved net loss (-$190M vs -$367M Q4 2024), maintaining 2026 guidance (3.1-4.2 GW); other trends include AlTi's $93B AUM and Amrize's $11.8B 2025 revenue. No widespread insider selling/buying noted, but capital allocation via bonuses (High Roller CEO $250K), severance (Eos, Bogota), and RSUs (HF Sinclair Acting CEO ~$105K) indicates retention focus. Portfolio implications: Stability in finance/biotech (e.g., First Foundation merger-ready exec fixes), but monitor successor gaps (Barinthus PAO, MSCI CAO) for operational risks; alpha in pre-catalyst firms like Immunic (Phase 3 data E2026).

40 high priority 40 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 31, 2026

Two biotech/pharma companies, Lipella Pharmaceuticals Inc. and IO Biotech, Inc., filed for bankruptcy within two days (March 30-31, 2026), signaling acute distress in the emerging growth biotech sector amid funding challenges and operational failures. Both filings carry maximal materiality (10/10) with uniformly negative sentiment, warning shareholders of highly speculative trading, substantial total loss risks, and no expected recoveries. No positive period-over-period trends evident; instead, implied severe deterioration led to Chapter 11 (Lipella, reorganization) and Chapter 7 (IO Biotech, liquidation) proceedings, with IO Biotech ceasing all operations, terminating staff/leadership, and defaulting on a €22.5M EIB loan. Key market implication: Nasdaq-listed IOBT and Lipella shares decouple from fundamentals, presenting extreme volatility and downside. Portfolio-level pattern: Cluster of insolvencies highlights biotech funding winter, with no capital allocation (dividends/buybacks), insider activity, or forward guidance beyond liquidation warnings.

2 high priority 2 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 31, 2026

Across 40 filings in the USA Board Room Changes stream (36 new), the dominant theme is executive and board transitions, with 22 appointments/promotions (e.g., experienced directors/CEOs in biotech, banking, wealth mgmt) and 18 resignations/retirements, 70% neutral sentiment, 25% positive, 5% negative/mixed. A cluster of 9 iShares ETF filings reveals BlackRock's uniform leadership shift appointing Jay Jacobs (ex-Global X ETFs, BlackRock equity ETFs head) as Sponsor CEO/President replacing Shannon Ghia across Gold, Bitcoin, Silver, Ethereum, etc., signaling consolidated ETF oversight amid crypto/commodity volatility. Financial trends limited but notable: T1 Energy improved Q4 2025 net loss 48% YoY ($367.2M to $190M), full-year loss narrowed 15% YoY, maintained 2026 production guidance 3.1-4.2 GW with $375-450M EBITDA run-rate 2027. Positive capital allocation in High Roller ($250k CEO bonus), T1 ($160M PTC sale at $0.91/watt), HF Sinclair (RSU grants to acting CEO); no broad insider trading but smooth successions imply management conviction. Portfolio-level: Banking/fintech shows merger-driven stability (First Foundation April 1 close), biotech adds commercialization expertise pre-catalysts (Immunic Phase 3 data E2026), overall bullish for growth sectors via expertise infusion but watch unnamed successors.

40 high priority 40 total filings
· daily

US Merger & Acquisition SEC Filings — March 31, 2026

Across 10 US SEC filings focused on M&A and takeover activity in the period ending March 31, 2026, a surge in deal completions dominates, including 4 de-SPAC mergers/IPOs/amendments (Trailblazer/Cyabra, Soulpower, Spartacus, Inflection Point, Live Oak), 3 acquisitions (SCYNEXIS, Spire, Oramed/Lifeward), 2 divestitures (BrightSpring, Oramed), and 1 share authorization (Mobivity), signaling robust M&A momentum in biotech, utilities, health services, and SPACs. No explicit period-over-period financial declines reported; instead, themes of portfolio optimization via divestitures and bolt-on acquisitions highlight strategic refocusing without margin compression or YoY revenue drops noted. SPAC activity is particularly hot with 5 filings, pro forma valuations up to $8.5B (Soulpower), and trading commencements imminent. Positive sentiment prevails in 7/10 filings (avg materiality 8.5/10), with forward-looking catalysts like Phase 2 trials (SCYNEXIS Q4 2026) and EPS growth targets (Spire 5-7%). Mixed/neutral tones in Soulpower (closing delay), Live Oak, and Mobivity flag execution risks. Implications: Investors should prioritize post-deal liquidity events and pipeline readouts for alpha, as capital allocation favors growth via M&A over buybacks/dividends.

10 high priority 10 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 31, 2026

Across 50 overnight SEC filings, mixed sentiment dominates with 14 mixed, 9 positive, 5 negative, and 22 neutral, reflecting resilient capital allocation amid uneven operational trends; energy firms like AleAnna and Dawson show strong YoY EBITDA growth (AleAnna $6.6M FY, Dawson +139% to $4.7M) offset by renewable losses and flat margins, while biotechs (Aktis, DiaMedica, OS Therapies) report clinical progress but widening net losses (OS +224% to $28.8M). Financials and REITs emphasize shareholder returns via buybacks (First Northern 6% of shares ~$15.6M, News Corp $1B program) and dividends (SmartStop $1.60 annualized, AGL $0.60/share), alongside credit expansions (Prologis global facility, Ares 3-year term loan). M&A activity surges in defense/tech (Red Cat $25M Quaze + Apium acquisitions) and resources (Range Impact coal mines boosting assets 20x to $123M), but SPACs and crypto (Solana $40.9M FY loss despite $325M Q4 net income) highlight volatility. Portfolio-level trends include 7/15 reporting entities with revenue growth >20% YoY (e.g., Dawson Q4 +67%), but 6/12 with margin stability or compression; activist push at Lululemon (8.6% stake, proxy fight) signals governance risks. Key implications: Favor buyback-heavy financials and acquisition-driven small caps pre-market, monitor biotech catalysts into mid-2026.

33 high priority 17 medium 50 total filings